Partners of the INTERCEPT-T2D consortium are highly renowned in the field of diabetes and have extensive knowledge of the disease.
This unique collaboration will give a new scale to the evidence available regarding the subclassification of T2D based on relevant inflammatory parameters and suggestion of a novel anti-inflammatory therapy that may intercept the disease transition.
